Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J. Frigault, Philippe Armand, Robert Redd, et al.
Blood Advances (2020) Vol. 4, Iss. 1, pp. 122-126
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management
Sandra Susanibar‐Adaniya, Stefan K. Barta
American Journal of Hematology (2021) Vol. 96, Iss. 5, pp. 617-629
Open Access | Times Cited: 253
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Hao Wang, Gurbakhash Kaur, Alexander Sankin, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 154
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Elise A. Chong, Cécile Alanio, Jakub Svoboda, et al.
Blood (2021) Vol. 139, Iss. 7, pp. 1026-1038
Open Access | Times Cited: 122
New agents and regimens for diffuse large B cell lymphoma
Liang Wang, Linrong Li, Ken H. Young
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 122
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas
Wei Xie, L. Jeffrey Medeiros, Shaoying Li, et al.
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 4, pp. 372-381
Closed Access | Times Cited: 70
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Marc Armengol, Juliana C. Santos, Miranda Fernández-Serrano, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 214-214
Open Access | Times Cited: 42
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
Prokop Vodička, Pavel Klener, Marek Trnĕný
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1481-1501
Open Access | Times Cited: 33
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
Tingxun Lu, Jie Zhang, Zijun Y. Xu‐Monette, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Immune checkpoint blockade in hematological malignancies: current state and future potential
Prateek Pophali, Juan Carlos Varela, Jacalyn Rosenblatt
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma
Xiangke Xin, Xiaojian Zhu, Yang Yang, et al.
Cellular Oncology (2024) Vol. 47, Iss. 4, pp. 1425-1440
Closed Access | Times Cited: 5
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas
Francesco D’Alò, Silvia Bellesi, Elena Maiolo, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2243-2243
Open Access | Times Cited: 5
Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment
Andreea Daniela Gheorghe, Miruna Cristian, Eliza Calin, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 853-853
Open Access
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
Dipenkumar Modi, Bindu Potugari, Joseph P. Uberti
Cancers (2021) Vol. 13, Iss. 22, pp. 5827-5827
Open Access | Times Cited: 32
DLBCL 1L—What to Expect beyond R-CHOP?
Maike Stegemann, Sophy Denker, Clemens A. Schmitt
Cancers (2022) Vol. 14, Iss. 6, pp. 1453-1453
Open Access | Times Cited: 22
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Sotirios G. Papageorgiou, Thomas Thomopoulos, Athanasios Liaskas, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 1917-1917
Open Access | Times Cited: 20
Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth
Lutz Menzel, Uta E. Höpken, Armin Rehm
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 30
PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma
Mohammad Jalili‐Nik, Arash Soltani, Baratali Mashkani, et al.
International Immunopharmacology (2021) Vol. 98, pp. 107870-107870
Closed Access | Times Cited: 25
Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Wenwen Yang, Caining Lei, Shaoming Song, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 24
How I treat secondary CNS involvement by aggressive lymphomas
Juan Pablo Alderuccio, Lakshmi Nayak, Kate Cwynarski
Blood (2023) Vol. 142, Iss. 21, pp. 1771-1783
Closed Access | Times Cited: 10
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
Mwanasha H. Merrill, Parastoo B. Dahi, Robert Redd, et al.
Blood (2023) Vol. 142, Iss. 7, pp. 621-628
Open Access | Times Cited: 9
Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma
Reid W. Merryman, Justin Rhoades, Kan Xiong, et al.
HemaSphere (2024) Vol. 8, Iss. 4
Open Access | Times Cited: 3
Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies
Inna Serganova, Sanjukta Chakraborty, Samuel Yamshon, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 14
PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
Joshua W.D. Tobin, Karolina Bednarska, Ashlea Campbell, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1152-1152
Open Access | Times Cited: 18
PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
Wei Xie, L. Jeffrey Medeiros, Shaoying Li, et al.
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1587-1587
Open Access | Times Cited: 11
Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond
Salvatore Perrone, Paolo Lopedote, Vitaliana De Sanctis, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2751-2751
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top